key: cord-0820849-4a28af7t
authors: Bahadur Gurung, Arun; Ajmal Ali, Mohammad; Lee, Joongku; Abul Farah, Mohammad; Mashay Al-Anazi, Khalid
title: Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme
date: 2020-07-17
journal: J King Saud Univ Sci
DOI: 10.1016/j.jksus.2020.07.007
sha: c0adc9ed820ceabcfddaffc88a72297fba5d493c
doc_id: 820849
cord_uid: 4a28af7t

Coronaviruses are enveloped positive-strand RNA viruses belonging to family Coronaviridae and order Nidovirales which cause infections in birds and mammals. Among the human coronaviruses, highly pathogenic ones are Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) which have been implicated in severe respiratory syndrome in humans. There are no approved antiviral drugs or vaccines for the treatment of human CoV infection to date. The recent outbreak of new coronavirus pandemic, coronavirus disease 2019 (COVID-19) has caused a high mortality rate and infections around the world which necessitates the need for the discovery of novel anti-coronaviral drugs. Among the coronaviruses proteins, 3C-like protease (3CL(pro)) is an important drug target against coronaviral infection as the auto-cleavage process catalysed by the enzyme is crucial for viral maturation and replication. The present work is aimed at the identification of suitable lead molecules for the inhibition of 3CL(pro) enzyme via a computational screening of the Food and Drug Administration (FDA) approved antiviral drugs and phytochemicals. Based on binding energies and molecular interaction studies, we shortlisted five lead molecules (both FDA approved drugs and phytochemicals) for each enzyme targets (SARS-CoV-2 3CL(pro), SARS-CoV 3CL(pro) and MERS-CoV 3CL(pro)). The lead molecules showed higher binding affinity compared to the standard inhibitors and exhibited favourable hydrophobic interactions and a good number of hydrogen bonds with their respective targets. A few promising leads with dual inhibition potential were identified among FDA approved antiviral drugs which include DB13879 (Glecaprevir), DB09102 (Daclatasvir), molecule DB09297 (Paritaprevir) and DB01072 (Atazanavir). Among the phytochemicals, 11646359 (Vincapusine), 120716 (Alloyohimbine) and 10308017 (Gummadiol) showed triple inhibition potential against all the three targets and 102004710 (18-Hydroxy-3-epi-alpha-yohimbine) exhibited dual inhibition potential. Hence, the proposed lead molecules from our findings can be further investigated through in vitro and in vivo studies to develop into potential drug candidates against human coronaviral infections.

have been implicated in severe respiratory syndrome in humans. There are no approved antiviral drugs or vaccines for the treatment of human CoV infection to date. The recent outbreak of new coronavirus pandemic, coronavirus disease 2019 has caused a high mortality rate and infections around the world which necessitates the need for the discovery of novel anti-coronaviral drugs. Among the coronaviruses proteins, 3C-like protease (3CL pro ) is an important drug target against coronaviral infection as the autocleavage process catalysed by the enzyme is crucial for viral maturation and replication. The present work is aimed at the identification of suitable lead molecules for the inhibition of 3CL pro enzyme via a computational screening of the Food and Drug Administration (FDA) approved antiviral drugs and phytochemicals. Based on binding energies and molecular interaction studies, we shortlisted five lead molecules (both FDA approved drugs and phytochemicals) for each enzyme targets (SARS-CoV-2 3CL pro , SARS-CoV 3CL pro and MERS-CoV 3CL pro ). The lead molecules showed higher binding affinity compared to the standard inhibitors and exhibited favourable hydrophobic interactions and a good number of hydrogen bonds with their respective targets. A few promising leads with dual inhibition potential were identified among FDA approved antiviral drugs which include DB13879 (Glecaprevir), DB09102 (Daclatasvir), molecule DB09297 (Paritaprevir) and DB01072 (Atazanavir). Among the phytochemicals, 11646359 (Vincapusine), 120716 (Alloyohimbine) and 10308017 (Gummadiol) showed triple inhibition potential against all the three targets and 102004710 (18-Hydroxy-3-epi-alpha-yohimbine) exhibited dual inhibition potential. Hence, the proposed lead molecules from our findings can be further investigated through in vitro and in vivo studies to develop into potential drug candidates against human coronaviral infections.

Keywords: Coronaviruses, 3C-like protease, SARS-CoV, MERS-CoV, molecular docking, virtual screening, FDA approved drugs, antiviral drugs, phytochemicals

Coronaviruses belong to the Coronavirinae subfamily, family Coronaviridae and order Nidovirales. The subfamily members based on genomic structure and phylogenetic study can be classified under four genera -Alpha-, Beta-, Gamma-and Delta-coronavirus (Cui et al., 2019) . The first two genera cause infections in only mammals while birds and mammals are commonly infected by Gamma-and Delta-coronaviruses (Woo et al., 2012) . While Alpha-coronaviruses and Beta-coronaviruses are known to cause gastroenteritis in animals, in humans, they commonly cause respiratory distress (Cui et al., 2019) . There are four human coronaviruses such as HCoV-229E, HKU1, HCoV-NL63 and HCoV-OC43 which induce mild upper respiratory infections and two highly pathogenic ones, such as Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) implicated in severe respiratory syndrome in humans (Forni et al., 2017; Su et al., 2016) . All human coronaviruses are reported to have animal origins based on the current sequence studies, for example, SARS-CoV, MERS-CoV, HCoV-229E and HCoV-NL63 have been originated in bats while HKU1 and HCoV-OC43 are probably linked to rodents (Forni et al., 2017; Su et al., 2016) . The intermediate hosts such as domestic animals may play a significant role in facilitating the easy transfer of viruses from natural hosts to humans (Cui et al., 2019) . Furthermore, domestic animals themselves are susceptible to bat-borne or closely related coronavirus diseases (Lacroix et al., 2017; Simas et al., 2015) .

At present, 7 of 11 species of Alpha-coronavirus specified by the International Committee on Taxonomy of Viruses (ICTV) and 4 of 9 species of Beta-coronavirus have been reported only in bats. Consequently, bats are probably the main natural reservoirs of Alpha-and Betacoronaviruses (Woo et al., 2012) .

Coronaviruses are enveloped viruses of about 80 to 120 nm in diameter, with round and often pleiomorphic virions. They contain positive-strand RNA, with the largest genome (~30kb) known till date (Lai, 2001) . A helical capsid found within the viral membrane is composed of genomic RNA complexed with the basic nucleocapsid (N) protein. All coronaviruses display at least three membrane viral proteins. This includes type I glycoprotein, spike (S) protein which forms peplomers on the surface and gives a characteristic crown-like appearance, the membrane (M) protein and a small membrane protein, an envelope protein (E). All coronaviruses have a similar genomic structure (Weiss and Navas-Martin, 2005) . The replicase gene located within 5′ region approximately 20 to 22 kb encodes several enzymatic activities. The gene products of the replicase are encoded within two very large open reading frames, ORFs 1a and 1b, which are translated by a frameshift mechanism into two large polypeptides, pp1a and pp1ab (Gorbalenya, 2001; Lee et al., 1991) . With the help of S protein, coronaviruses bind to their specific host cellular receptors. On gaining entry into the cell, pp1a and pp1ab are translated from the viral genome RNA, ORFs 1a and 1b (Bredenbeek et al., 1990; Brian and Baric, 2005) . The ORF1a encodes a picornavirus 3C-like protease (3CL pro ) and one or two papain-like proteases (PL pro or PLP). These proteases catalyze the processing of viral pp1a and pp1ab into the mature replicase proteins (Lee et al., 1991; Ziebuhr et al., 2001) . The enzymes such as RNA-dependent RNA polymerase (RdRp), a helicase (116) and others are encoded in ORF 1b and processed from pp1ab (Gorbalenya, 2001) . The metabolism of coronavirus RNA and disruption of host cell processes are believed as a result of the catalytic activities of various enzymes (Ziebuhr, 2005) .

As aforementioned, SARS-and MERS-CoVs genome harbours two ORFs: ORF1a and ORF1b wherein ORF1a encodes two cysteine proteases viz; a papain-like protease (PL pro ) and a 3C-like protease (3CL pro ) also known as main protease (M pro ). While PL pro manages cleavage on the first three cutting sites of its polyprotein, 3CL pro is responsible for cleavage at other eleven positions causing the release of sixteen non-structural proteins (nsp) (Jo et al., 2020) . The crystal structures of SARS-and MERS-CoVs 3CL pro reveal the presence of three structural domains in each monomer wherein domains I and II has a characteristic chymotrypsin-like fold with a catalytic cysteine and are linked to a third C-terminal domain by a long loop (Needle et al., 2015) . Therefore, 3CL pro is an important drug target against coronaviral infection as the auto-cleavage process is indispensable for viral maturation and replication (Jo et al., 2020) .

The recent outbreak of new coronavirus pandemic or coronavirus disease 2019 has caused high mortality rate and infections around the world (Wu et al., 2020; Zhou et al., 2020) warrants the need for the discovery of new effective antiviral therapeutics against coronaviral infections. There are no approved antiviral drugs or vaccines for the treatment of human CoV infection to date, though many candidate therapeutics have been investigated in pre-clinical studies (Abd El-Aziz and Stockand, 2020; Dhama et al., 2020; Graham et al., 2013; Lundstrom, 2020; Padron-Regalado, 2020) . Although many attempts have been previously made by workers to identify specific inhibitors for 3CL pro enzymes, a few studies have been done to target all the three coronavirus protease enzymes (SARS-CoV-2 3CL pro , SARS-CoV 3CL pro and MERS-CoV 3CL pro ) using small molecules. In this study we aimed at finding suitable lead molecules for the inhibition of 3CL pro enzymes through virtual screening of two chemical datasets viz; Food and Drug Administration (FDA) approved antiviral drugs and selected phytochemicals. We have proposed five lead molecules as potential inhibitors for each enzyme targets. These lead molecules could be further investigated for developing as drugs against anti-coronaviral infection.

A total of 263 phytochemicals and 75 FDA approved antiviral drugs were retrieved from the database of Indian Plants, Phytochemistry And Therapeutics (IMPPAT) (Mohanraj et al., 2018) and DrugBank database (Wishart et al., 2008) respectively. The three-dimensional structure of the molecules was downloaded in SDF format and the molecules whose only two-dimensional structures were available, were converted into the three-dimensional form using OpenBabel software version 2.4.1 (O'Boyle et al., 2011) and optimized using the Merck molecular force field (MMFF94) (Halgren, 1996) .

The drug-like compounds from the phytochemicals set were filtered based on Lipinski's rule of five (Lipinski, 2004 ), Veber's rule (Veber et al., 2002) and Adsorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) physicochemical parameters. The physicochemical properties of the compounds were evaluated using DataWarrior program version 5.0 (Sander et al., 2015) .

The high resolution three dimensional X-ray crystal structures of the enzyme target: SARS-CoV-2 3CL pro , SARS-CoV 3CL pro and MERS-CoV 3CL pro were retrieved from protein data bank (PDB) (http://www.rcsb.org/) using their accession IDs 6Y2F, 3TNT and 5WKK at a resolution of 1.95 Å, 1.59 Å and 1.55 Å respectively. The heteroatoms including ions, cocrystal ligands (O6K, G85 and AW4 corresponding to PDB IDs: 6Y2F, 3TNT and 5WKK respectively) and water molecules were removed. Hydrogen atoms and Kolmann charges were added to the protein using AutoDockTools 1.5.6 (Morris et al., 2009) and the proteins were converted into PDBQT format.

The selected compounds were prepared for docking using AutoDockTools 1.5.6 (Morris et al., 2009) . Hydrogen atoms and Gasteiger charges were added to the selected compounds and the torsions were defined for each compound. The structures were saved in PDBQT format.

The binding affinity of each selected compound along with the control with the three enzyme targets was determined using molecular docking approach. The binding sites for the docking were defined by placing a grid box of suitable dimensions centred at each cocrystallized ligand ( Table 1) . Autodock Vina was used for carrying out molecular docking, which performs docking calculations based on sophisticated gradient optimization method (Trott and Olson, 2010) . The binding poses were clustered and ranked in the order of their binding affinities. The molecular interactions (hydrogen bonds and hydrophobic interactions between the target proteins and compounds were studied using LigPlot+ version 1.4.5 (Laskowski and Swindells, 2011) .

A set of 75 FDA approved antiviral drugs and 263 phytochemicals belonging to different classes such as prenol lipids, flavonoids, indoles and derivatives, alkaloids, lignans, organooxygen compounds etc. were used for the present study. Since the FDA approved drugs have already undergone the preclinical and clinical trials and tested safe in patients, the drugs were not tested again using in silico drug-like filters. While plant-derived compounds are much safer to use with fewer adverse effects, we subjected them into virtual screening protocol to reduce the drug-attrition rate. We used the rule of five (ROF) and Veber's rule filters to test the oral bioavailability of the compounds. According to ROF, a compound is considered to be orally bioactive if their physicochemical properties lie within the safe limits (molecular weight ≤500 Da, hydrogen bond donors ≤5, hydrogen bond acceptors ≤10, and an octanol-water partition coefficient log P ≤ 5) (Lipinski, 2004 ). Veber's rule states that a good oral bioavailable compound possesses number of rotatable bonds ≤10 and topological polar surface area ≤140 Å 2 (Veber et al., 2002) . Further, the molecules were also tested for in silico toxicity studies. Out of 263 phytochemicals, 46 molecules were found to be orally bioactive, non-tumorigenic, non-mutagenic, non-irritant and without any side effects on reproductive health. Thus, these 46 phytochemicals and 75 FDA approved drugs were tested further for their inhibitory potential against the three enzyme targets ( Table 2 and Table 3 ). 

Among the FDA approved antiviral drugs, we found that DB13879 (Glecaprevir) and DB09102 (Daclatasvir) can be potential leads for dual inhibition of SARS-CoV-2 3CL pro (Figure 1 A-B) and SARS-CoV 3CL pro as they were common top 5 leads. The lead molecule DB09297 (Paritaprevir) can be explored as a dual inhibitor of SARS-CoV-2 3CL pro ( (Khare, 2007) . Gummadiol belongs to the class of Furanoid lignans which can be extracted from Gmelina arborea (Anjaneyulu et al., 1975; Pathala et al., 2015) .

Alloyohimbine and 18-Hydroxy-3-epi-alpha-yohimbine are alkaloids which are isomeric forms of yohimbine, an alkaloid extracted from the bark of the tree Pausinystalia yohimbe and has been traditionally used for the treatment of sexual disorders (Anadón et al., 2016) .

However, the bioactivity of these compounds against viral infections have not been reported till date to the best of our knowledge and therefore these are novel phytochemical leads which could be further explored against coronavirus infections in humans. The key findings from the present study has been illustrated with Figure 3 .

The present work is an in silico attempt to propose lead molecules as potential inhibitors of coronavirus 3CL pro enzyme. Our study unravels new chemical entities from a repertoire of phytochemicals and FDA approved drugs that could be repurposed for treatment of coronavirus infection in humans. The leads suggested from this study could offer new candidate molecules in the drug discovery pipeline for the treatment and management of the disease. The current work is limited by small datasets and therefore, it would be worth exploring new chemical databases with big ligand sets for virtual screening procedure for identification of novel inhibitors against the target enzyme. A combined molecular docking and molecular dynamics simulation approach could be envisaged which would further provide useful mechanistic insights into the binding modes of inhibitions at the atomic level.

Further research work is necessary to establish the inhibitory activity of the identified FDA approved lead molecules against the coronavirus 3CL pro enzyme through in vitro and in vivo experiments.

The authors report no conflicts of interest in this work. cLogP: octanol-water partition coefficient; cLogS: aqueous solubility at 25° and pH=7.5;

HBA: hydrogen bond acceptor; HBD: hydrogen bond donor; TPSA (Å 2 ): Topological polar 

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status

Interactions between Nutraceuticals/Nutrients and Therapeutic Drugs

The structure of gummadiol-a lignan hemi-acetal

The primary structure and expression of the second open reading frame of the polymerase gene of the coronavirus MHV-A59; a highly conserved polymerase is expressed by an efficient ribosomal frameshifting mechanism

Coronavirus genome structure and replication

Origin and evolution of pathogenic coronaviruses

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

152 -Drugs for HIV Infection

KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis

Molecular evolution of human coronavirus genomes

Big nidovirus genome

A decade after SARS: strategies for controlling emerging coronaviruses

Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

Treatment of hepatitis C: Results in real life

Inhibition of SARS-CoV 3CL protease by flavonoids

Indian Medicinal Plants: An Illustrated Dictionary

Genetic diversity of coronaviruses in bats in Lao PDR and Cambodia

Coronaviridae: the viruses and their replication

LigPlot+: multiple ligand-protein interaction diagrams for drug discovery

The complete sequence (22 kilobases) of murine coronavirus gene 1 encoding the putative proteases and RNA polymerase

Lead-and drug-like compounds: the rule-of-five revolution

Coronavirus Pandemic-Therapy and Vaccines

IMPPAT: A curated database of I ndian M edicinal P lants

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity

Open Babel: An open chemical toolbox

Vaccines for SARS-CoV-2: lessons from other coronavirus strains

A review on gambhari (Gmelina arborea Roxb.)

DataWarrior: an open-source program for chemistry aware data visualization and analysis

Bat coronavirus in Brazil related to appalachian ridge and Porcine epidemic diarrhea viruses

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Molecular properties that influence the oral bioavailability of drug candidates

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol

DrugBank: a knowledgebase for drugs, drug actions and drug targets

Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavi

others, 2020. A new coronavirus associated with human respiratory disease in China

others, 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin

The coronavirus replicase

The autocatalytic release of a putative RNA virus transcription factor from its polyprotein precursor involves two paralogous papainlike proteases that cleave the same peptide bond

The authors would like to extend their sincere appreciation to the Deanship of Scientific